Quick Answer
IOVANCE BIOTHERAPEUTICS, INC. reported Diluted EPS of $1.09 per share (loss) for fiscal year 2025.
IOVANCE BIOTHERAPEUTICS, INC. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.09 | +14.8% |
| 2024 | -$1.28 | +32.3% |
| 2023 | -$1.89 | +24.1% |
| 2022 | -$2.49 | -11.7% |
| 2021 | -$2.23 | -18.6% |
| 2020 | -$1.88 | -18.2% |
| 2019 | -$1.59 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| June 30, 2025 | -$0.33 | +2.9% | +8.3% |
| March 31, 2025 | -$0.36 | +14.3% | -28.6% |
| September 30, 2024 | -$0.28 | +39.1% | +17.6% |
| June 30, 2024 | -$0.34 | +27.7% | +19.0% |
| March 31, 2024 | -$0.42 | +16.0% | +8.7% |
| September 30, 2023 | -$0.46 | +27.0% | +2.1% |
| June 30, 2023 | -$0.47 | +25.4% | +6.0% |
| March 31, 2023 | -$0.50 | +13.8% | +20.6% |
- IOVANCE BIOTHERAPEUTICS, INC. showed an increase of +14.8% in Diluted EPS compared to the prior fiscal year.
- Over the 2019–2025 period, IOVANCE BIOTHERAPEUTICS, INC.’s diluted eps has grown by 31.4% (from $1.59 per share (loss) to $1.09 per share (loss)).
- The most recent figure is from IOVANCE BIOTHERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: